Roche receives EU marketing authorisation for follicular lymphoma treatment
The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.